AbCellera Biologics Inc (NASDAQ:ABCL) has a beta value of 0.39 and has seen 1.03 million shares traded in the last trading session. The company, currently valued at $900.95M, closed the last trade at $3.05 per share which meant it lost -$0.23 on the day or -7.00% during that session. The ABCL stock price is -98.36% off its 52-week high price of $6.05 and 23.28% above the 52-week low of $2.34. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.91 million shares traded. The 3-month trading volume is 2.48 million shares.
The consensus among analysts is that AbCellera Biologics Inc (ABCL) is Buy stock at the moment, with a recommendation rating of 1.22. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 2 out of 9 have rated it as a Hold, with 7 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.15.
AbCellera Biologics Inc (NASDAQ:ABCL) trade information
Sporting -7.00% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the ABCL stock price touched $3.05 or saw a rise of 11.85%. Year-to-date, AbCellera Biologics Inc shares have moved 4.11%, while the 5-day performance has seen it change 4.11%. Over the past 30 days, the shares of AbCellera Biologics Inc (NASDAQ:ABCL) have changed 1.68%. Short interest in the company has seen 15.89 million shares shorted with days to cover at 6.42.
Wall Street analysts have a consensus price target for the stock at $5, which means that the shares’ value could jump 39.0% from current levels. The projected low price target is $5.0 while the price target rests at a high of $5.0. In that case, then, we find that the current price level is -63.93% off the targeted high while a plunge would see the stock gain -63.93% from current levels.
AbCellera Biologics Inc (ABCL) estimates and forecasts
Figures show that AbCellera Biologics Inc shares have underperformed across the wider relevant industry. The company’s shares have gained 8.94% over the past 6 months, with this year growth rate of -15.69%, compared to 17.00% for the industry. Revenue growth from the last financial year stood is estimated to be -16.95%.
10 analysts offering their estimates for the company have set an average revenue estimate of 7.58M for the current quarter. 3 have an estimated revenue figure of 11.81M for the next ending quarter. Year-ago sales stood 9.2M and 9.95M respectively for this quarter and the next, and analysts expect sales will shrink by -17.62% for the current quarter and -16.95% for the next.
ABCL Dividends
AbCellera Biologics Inc is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
AbCellera Biologics Inc (NASDAQ:ABCL)’s Major holders
Insiders own 27.93% of the company shares, while shares held by institutions stand at 39.64% with a share float percentage of 55.00%. Investors are also buoyed by the number of investors in a company, with AbCellera Biologics Inc having a total of 201.0 institutions that hold shares in the company. The top two institutional holders are BAKER BROS. ADVISORS LP with over 27.53 million shares worth more than $81.48 million. As of 2024-06-30, BAKER BROS. ADVISORS LP held 9.4033% of shares outstanding.
The other major institutional holder is BAILLIE GIFFORD & CO, with the holding of over 21.91 million shares as of 2024-06-30. The firm’s total holdings are worth over $64.86 million and represent 7.4852% of shares outstanding.
